Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT05756088
Other study ID # 2000034497
Secondary ID YSI-004
Status Suspended
Phase
First received
Last updated
Start date November 2024
Est. completion date September 2027

Study information

Verified date May 2024
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this research study is to understand if a blood test in people who have had heart transplants can detect and predict the following: - Blockages in the small blood vessels of the heart. - Whether small blockages can turn into more severe blockages in the future. Participants will undergo blood draws once every 3 months in the first year of the study (4 blood draws total, taking 15 minutes each) and their medical records will be reviewed for 3 years after the date they are enrolled in the study.


Description:

A prospective, single center, assessment of donor derived cell free DNA in subjects who are post-heart transplant to assess correlation with microvascular flow as assessed by myocardial flow reserve (MFR) on positron emission tomography (PET). Study design: This prospective, single center registry will enroll up to 88 subjects at Yale New Haven Health System (YNHHS). Patients who get PET scans for routine post-transplant surveillance will be included in the study. Up to an anticipated 44 subjects with low MFR and up to an anticipated 44 subjects with normal MFR will have dd-cf DNA drawn every 3 months for a year. Patient population: A total of 88 adults referred to have an annual PET stress test as part of routine post-transplant surveillance for cardiac allograft vasculopathy and who are at least 3 years from heart transplantation and meet all eligibility criteria will be enrolled. Diagnostic assessment: All subjects will have quarterly blood draws during the first year of enrollment to assess the levels of dd- cf DNA. All subjects will also undergo standard of care annual PET scans. Subject follow up: All subjects will have routine follow-up as clinically necessary based on standard of care. Screening and follow-up data collection will occur through the electronic medical record. Follow up duration: 3 years after enrollment. Primary endpoint: Elevated dd-cf DNA levels in subjects with low MFR compared to normal MFR at up to one year follow-up post-enrollment. Secondary Endpoints: The following secondary endpoints will be reported at 3 years post-enrollment based on the routine post-transplant standard of care: - Combined clinical events of rejection, reduction in ejection fraction, need for revascularization, myocardial infarction, heart failure admissions and death or need for retransplantation. - All-cause, cardiovascular, and non-cardiovascular mortality - Myocardial infarction (Fourth Universal Definition) - Revascularization (PCI or CABG) - Hospitalization for heart failure - Rejection - Decrease in ejection fraction from baseline echo to 3 years follow up. - Retransplantation Procedure summary: Patients will undergo routine post-transplant surveillance and management per the discretion of the treating physician and per YNHHS post-heart transplant protocols. Quarterly study blood draws will be conducted in the first year of the study and will include dd-cf DNA measurements. These results will not be available to study team or the patients. All study participants will be blinded to these results.


Recruitment information / eligibility

Status Suspended
Enrollment 88
Est. completion date September 2027
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Potential subjects must meet all of the following criteria to be eligible for inclusion in the study: General Inclusion Criteria: - The patient is over 18 years of age. - The patient underwent orthotopic heart transplantation and is undergoing routine cardiac allograft vasculopathy (CAV) surveillance with PET. - The patient has no evidence of cardiogenic shock. - The patient has no evidence of acute rejection. - The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC). Potential subjects will be excluded if any of the following conditions apply: Exclusion Criteria: - Evidence of moderate to large area of ischemia on the PET. - Multiorgan transplantation. - Life expectancy <1 year due to non-cardiac conditions. - Less than 3 years from transplantation. - Patient appears unlikely or unable to participate in the required study procedures, as assessed by the study PI, study coordinator, or designee (ex: clinically-significant psychiatric, addictive, or neurological disease).

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Blood draw to measure the levels of dd-cf DNA
Blood draw to measure the levels of dd-cf DNA.

Locations

Country Name City State
United States Yale New Haven Health New Haven Connecticut

Sponsors (3)

Lead Sponsor Collaborator
Yale University Natera, Inc., Yale Cardiovascular Research Group

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary dd-cf DNA and myocardial flow reserve (MFR) on positron emission tomography (PET) scan. Changes in dd-cf DNA levels in subjects with low MFR compared to normal MFR. Baseline up to 1 year
Secondary Impact of low MFR on rejection Changes in rates of rejection in participants with low MFR compared with normal MFR. 3 years
Secondary Impact of low MFR on left ventricular ejection fraction Changes in left ventricular ejection fraction in participants with low MFR compared with normal MFR. Baseline up to 3 years
Secondary Impact of low MFR on need for revascularization Changes in rates of need for revascularization in participants with low MFR compared with normal MFR. 3 years
Secondary Impact of low MFR on myocardial infarction (MI) Changes in rates of MI in participants with low MFR compared with normal MFR. 3 years
Secondary Impact of low MFR on admissions for heart failure Changes in number of admissions for heart failure in participants with low MFR compared with normal MFR. 3 years
Secondary Impact of low MFR on retransplantation Changes in rates of retransplantation in participants with low MFR compared with normal MFR. 3 years
Secondary Impact of low MFR on death Changes in rate of death in participants with low MFR compared with normal MFR. 3 years
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT04156711 - Remote Ischemic Preconditioning in Patients Undergoing Acute Minor Abdominal Surgery N/A
Recruiting NCT06133634 - Fisetin to Improve Vascular Function in Older Adults Phase 1/Phase 2
Completed NCT05872139 - Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging N/A
Recruiting NCT04558450 - Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN) N/A
Terminated NCT03325933 - Resistance Training and Cardiometabolic Health N/A
Not yet recruiting NCT05939934 - Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal N/A
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Recruiting NCT02334839 - The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction N/A
Recruiting NCT02020044 - Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) N/A
Completed NCT01775865 - Targeting Inflammation to Treat Cardiovascular Aging Phase 2
Completed NCT01691404 - Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO) N/A
Terminated NCT01412216 - The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance Phase 2
Completed NCT01319344 - Effect of Eplerenone on Endothelial Function in Metabolic Syndrome Phase 3
Completed NCT00990730 - Atherosclerosis in Rheumatoid Arthritis N/A
Completed NCT00987974 - Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury Phase 4
Completed NCT00848302 - Endothelial Function in Human Arteries Early Phase 1
Completed NCT00532844 - A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction Phase 2
Completed NCT00376246 - Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects Phase 4
Completed NCT00775099 - Combustion Derived Air Pollution and Vascular Function N/A